Drawing for PROGENTEC DIAGNOSTICS

USPTO serial 88258685

PROGENTEC DIAGNOSTICS

Reviewed by CopyMark Law Group

Reg. 6005176Status 710
Filing date
Status date
Registration date
Mar 10, 2020
Examiner
WELLS, KELLEY L
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with PROGENTEC DIAGNOSTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Edwin Flores

EDWIN FLORES CHALKER FLORES, LLP14951 N DALLAS PARKWAYSUITE 400DALLAS, TX 75254

Goods and services

ClassDescriptionStatusFirst use
035Business consulting and management in the field of clinical trials, namely, patient enrollment tracking and monitoring, pharmaceutical and medicine tracking; business consulting and management in the field of clinical trials, namely, compilation of statistics and clinical trial data for business purposes; preparing and placing advertisements for others; providing referrals of patients for enrollment in clinical trials; business consulting and management in the field of clinical trials, namely, clinical data management; marketing consulting, namely, designing and developing advertising and marketing for others in relation to clinical trials and medical research; online business networking services for clinical research professionals involved in the clinical study of medical products including pharmaceuticals, biologics, diagnostic tools and medical devices; management and compilation of computerized databases of clinical research professionals to provide ability to contact clinical research professionals electronically including by email to evaluate clinical study protocols, take part in clinical studies and recruit patients to take part in clinical studies; promoting public awareness of the need for improved prevention and treatment of illnesses, and for improved health care quality and efficiency; public advocacy to promote awareness of the need for assuring patients safe access to affordable medicine; promoting technical and scientific investigation, research, and experimentation in the field of advancement of the application of scientific discovery in connection with pharmaceuticals, diagnostic tools, biomarkers and medical devices; and public advocacy to promote awareness of scientific, research and medical advancesSECTION 8 - CANCELLEDJan 11, 2019
038Providing access to a computer database; providing on-line forums for transmission of messages among computer and mobile device users concerning patient, doctor and caregiver information in order to generate, manage and share medical information; and provision of access to databasesSECTION 8 - CANCELLEDJan 11, 2019
042Medical and scientific research and development in the field of medicine, the prevention, treatment, management of illness and health care delivery; medical and scientific research in the field of illness and diagnosis; technical research in the field of pharmaceutical studies; pharmaceutical product evaluation; development of pharmaceutical tools, preparations and medicines; conducting early evaluations in the field of new pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; chemical, biochemical, biological and bacteriological research and analysis; biological research; medical laboratories; scientific and technological services and research and design relating thereto, namely, scientific analysis in the fields of pharmaceutical and medical device /diagnostics development; scientific research for medical purposes; design and development of computer software; research services for medical and pharmaceutical purposes; design and development of new products/services for others; design and development of computer tracking and diagnostic tools; conducting clinical trials for others; medical laboratory services; providing information about the results of clinical trials for pharmaceutical products; electronic data storage; and working on and evaluation of biomarkers and diagnostic products; and providing an online network service that enables users to share data in the field of healthcare; non-downloadable computer software provided via the Internet as an Application Service Provider ASP-hosted solution for the collection, editing, organizing, modifying, book marking, transmission, storage and sharing of data and informationSECTION 8 - CANCELLEDJan 11, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 25, 2026C8..CANCELLED SEC. 8 (6-YR)—
Mar 10, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Mar 10, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 24, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 24, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 4, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 18, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 18, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Nov 18, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 18, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 18, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
May 7, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 25, 2019ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Apr 23, 2019PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Apr 3, 2019ALIEASSIGNED TO LIE—
Mar 13, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 13, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Mar 13, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 13, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 13, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 5, 2019DOCKASSIGNED TO EXAMINER—
Feb 2, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 15, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance